Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Petro C, González PA, Cheshenko N, Jandl T, Khajoueinejad N, Bénard A, Sengupta M, Herold BC, Jacobs WR.

Elife. 2015 Mar 10;4. doi: 10.7554/eLife.06054.

2.
3.

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.

Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI.

J Virol. 2015 Nov 11;90(1):562-74. doi: 10.1128/JVI.01845-15. Print 2016 Jan 1.

4.

A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.

Burn C, Ramsey N, Garforth SJ, Almo S, Jacobs WR Jr, Herold BC.

J Infect Dis. 2018 Feb 14;217(5):754-758. doi: 10.1093/infdis/jix628.

5.

Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.

Wizel B, Persson J, Thörn K, Nagy E, Harandi AM.

Vaccine. 2012 Jun 19;30(29):4361-8. doi: 10.1016/j.vaccine.2012.02.019.

PMID:
22682292
6.

Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.

Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F.

J Virol. 2011 May;85(10):5036-47. doi: 10.1128/JVI.02548-10. Epub 2011 Mar 9.

8.

Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅ.

J Virol. 2012 Jul;86(14):7544-53. doi: 10.1128/JVI.00186-12. Epub 2012 May 2.

9.

Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.

Li X, Zhang S, Lei J, Zhu Y, Zhou X, Xiao J, Xiang T.

Int Immunopharmacol. 2018 Aug;61:100-108. doi: 10.1016/j.intimp.2018.05.024. Epub 2018 May 29.

PMID:
29857239
10.

Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.

Wang M, Jiang S, Zhou L, Wang C, Mao R, Ponnusamy M.

Arch Virol. 2017 Mar;162(3):701-711. doi: 10.1007/s00705-016-3154-7. Epub 2016 Nov 21.

PMID:
27868164
11.

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR.

Vaccine. 1996 Sep;14(13):1230-4.

PMID:
8961510
12.

Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.

Tengvall S, O'Hagan D, Harandi AM.

Antiviral Res. 2008 Jun;78(3):202-14. doi: 10.1016/j.antiviral.2007.12.014. Epub 2008 Jan 24.

PMID:
18276020
15.

Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.

Visalli RJ, Natuk RJ, Kowalski J, Guo M, Blakeney S, Gangolli S, Cooper D.

Vaccine. 2014 Mar 10;32(12):1398-406. doi: 10.1016/j.vaccine.2013.10.079. Epub 2014 Jan 24.

PMID:
24462481
16.
17.

Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.

Bernard MC, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, Londono-Hayes P.

PLoS One. 2015 Apr 2;10(4):e0121518. doi: 10.1371/journal.pone.0121518. eCollection 2015.

20.

Supplemental Content

Support Center